Sells plant-based supplements for heart, brain and immune health to consumers, and provides contract manufacturing and formulation services to third parties.
10-K for FY2025, filed Apr 9, 2026We are a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals. Our proprietary and…View ↗
Nutraceuticals are generally considered to be substances that beyond their nutritional value can be used to achieve a benefit for an…View ↗
Guided by this mission, our first two acquisitions (in 2019 and 2020, respectively) formed our historical operating subsidiaries, Bergamet…View ↗
The company sells plant-based supplements through its websites, online marketplaces and other channels, and manufactures white-label products for third parties; customers generally pay before shipment unless they have agreed terms.
10-K for FY2025, filed Apr 9, 2026
$4.5M
10-K for FY2025, filed Apr 9, 2026
$4.5M ↗
Consumers buy directly through company websites and online marketplaces, while retail and health-care platforms offer other routes; third parties buy white-label products from its manufacturing operation.
10-K for FY2025, filed Apr 9, 2026Our approach to the market has been to implement a multi-channel marketing strategy that includes major eCommerce websites, distributors…View ↗
As a key part of our multi-channel strategy, Amazon.com has been generating strong sales, particularly with its popular ‘Subscribe & Save’…View ↗
We sell our products on Fullscript.com, the nation’s leading care delivery platform for integrative medicine. This makes select BergaMet…View ↗
The Fullscript launch followed the entry of our natural formulations for brain health into the retail marketplace through Natural Grocers…View ↗
The Company’s subsidiary, BergaMet N.A., LLC, recognizes revenue from its main source – e-commerce revenue. Its sales channels include the…View ↗
10-Q for Q2 FY2026, filed Aug 14, 2026
−$129.4KView ↗
8-K, filed May 18, 2026
Acquisition of Adli Gummies Inc. and the Imaraïs Beauty BrandView ↗
Growing. Revenue grew 2.7x in 4 years, from $1.7M in FY2021 to $4.5M in FY2025, about 28% a year.
Added contract manufacturing
The latest report adds contract manufacturing and formulation services for third parties through Gummy USA to the earlier plant-based nutraceutical product platform.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Apr 9, 2026We are a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals. Our…View ↗
Loading...